- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07653100
A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF
A PHASE 3 STUDY IN INDIA TO DESCRIBE THE SAFETY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN ADULTS
The purpose of this phase 3 multicenter, double-blinded, placebo-controlled study in India is to learn about the safety and immunogenicity of RSVpreF in adults.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Pfizer CT.gov Call Center
- Número de teléfono: 1-800-718-1021
- Correo electrónico: ClinicalTrials.gov_Inquiries@pfizer.com
Ubicaciones de estudio
-
-
Andhra Pradesh
-
Visakhapatnam, Andhra Pradesh, India, 530002
- Reclutamiento
- King George Hospital
-
-
Karnataka
-
Bangalore, Karnataka, India, 560060
- Reclutamiento
- BGS Global Institute of Medical Sciences (BGSGIMS)
-
Bangalore, Karnataka, India, 560085
- Reclutamiento
- Radhakrishna Multispeciality Hospital and IVF Center
-
Belagavi, Karnataka, India, 590001
- Reclutamiento
- Belagavi Institute of Medical Sciences - Belagavi
-
-
Maharashtra
-
Nashik, Maharashtra, India, 422003
- Reclutamiento
- Suyog Hospital
-
Pune, Maharashtra, India, 411043
- Reclutamiento
- Bharati Vidyapeeth {Deemed to be University) Medical College Hospital & Research Centre
-
-
National Capital Territory of Delhi
-
Dwarka, National Capital Territory of Delhi, India, 110075
- Reclutamiento
- Aakash Healthcare Private Limited
-
New Delhi, National Capital Territory of Delhi, India, 110060
- Reclutamiento
- Sir Ganga Ram Hospital
-
New Delhi, National Capital Territory of Delhi, India, 110029
- Reclutamiento
- All India Institute Of Medical Sciences
-
-
Rajasthan
-
Jaipur, Rajasthan, India, 302039
- Reclutamiento
- Maharaja Agrasen Superspeciality Hospital
-
-
Tamil Nadu
-
Chengalpattu, Tamil Nadu, India, 603203
- Reclutamiento
- SRM Medical College Hospital and Research Centre - Kattankulathur
-
Kelambākkam, Tamil Nadu, India, 603103
- Reclutamiento
- Chettinad Hospital and Research Institute
-
-
West Bengal
-
Kolkata, West Bengal, India, 700020
- Reclutamiento
- Institute of Post Graduate Medical Education & Research, SSKM Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Key Inclusion Criteria:
- Participants ≥18 years of age at Visit 1.
- Participants who are ambulatory and live independently in the community.
- Participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study.
- Applicable to participants 18 through 59 years of age: Participants who are healthy or have stable preexisting diseases. These participants are considered at high risk of RSV disease by having at least 1 reportable stable chronic medical condition(s) that belongs to 1 or more of the following:
- Chronic heart disease (ie, coronary artery disease, heart failure, or congenital heart disease)
- Chronic lung disease (ie, COPD, emphysema, asthma, interstitial lung disease, or cystic fibrosis)
- Nongestational diabetes mellitus type 1 or type 2
- Severe obesity (body mass index [BMI] ≥40 kg/m2)
- Chronic liver disease (ie, cirrhosis)
- Chronic kidney disease (not including end-stage renal disease with or without dialysis)
- Chronic neurological disease that causes impaired airway clearance or respiratory muscle weakness (ie, poststroke dysphagia, amyotrophic lateral sclerosis, or muscular dystrophy)
- Chronic hematologic disease (ie, sickle cell disease or thalassemia)
Note: A chronic medical condition for this study is defined as:
- Duration ≥6 months.
- Requires regular medical follow-up or ongoing prescribed medication or hospitalization in the previous year.
- Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent document (ICD) and in the protocol.
Key Exclusion Criteria:
- Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
- History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s) or any related vaccine.
- Prior history of any subtype of Guillain-Barré syndrome of any etiology.
- Serious chronic disorder, including metastatic malignancy, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the participant from participating in the study.
- Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
- Individuals who receive chronic systemic treatment with immunosuppressive therapy, including cytotoxic agents, immunosuppressive monoclonal antibodies, systemic corticosteroids, or radiotherapy, eg, for cancer or an autoimmune disease, from 60 days before study intervention administration or planned receipt throughout the study.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador de placebos: Placebo
Placebo |
Placebo |
|
Experimental: RSVpreF
RSVpreF Vaccine |
RSVpreF Vaccine |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Neutralizing Titers (NTs) for RSV A and RSV B expressed as Geometric Mean Titers (GMT)
Periodo de tiempo: Before vaccination, 1 month after vaccination
|
Before vaccination, 1 month after vaccination
|
|
|
NTs for RSV A and RSV B expressed as Geometric Mean Fold Rise (GMFR)
Periodo de tiempo: Before vaccination, 1 month after vaccination
|
Before vaccination, 1 month after vaccination
|
|
|
NTs for RSV A and RSV B expressed as seroresponse rate
Periodo de tiempo: 1 month after vaccination
|
1 month after vaccination
|
|
|
Proportion of participants reporting local reactions within 7 days following investigational product administration
Periodo de tiempo: Within 7 days
|
Describe local reactions following investigational product administration |
Within 7 days
|
|
Percentage of participants reporting systemic events within 7 days following investigational product administration
Periodo de tiempo: Within 7 days
|
Describe systemic events following investigational product administration |
Within 7 days
|
|
Percentage of participants reporting adverse events (AEs) through 1 month following investigational product administration
Periodo de tiempo: 1 month after vaccination
|
Describe AEs occurring through 1 month following administration of investigational product |
1 month after vaccination
|
|
Percentage of participants reporting serious adverse events (SAEs) throughout the study
Periodo de tiempo: 3 months after vaccination
|
Describe SAEs through 3 months following administration of investigational product |
3 months after vaccination
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Pfizer CT.gov Call Center, Pfizer
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
- C3671040
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .